IL-17A promotes cancer growth and progression by directly stimulating cancer cells via activation and translocation of NF-κB, STAT, and AP-1 and signalling that leads to the downstream activation of kinases, such as MAPK and HER1[6]. The gene discussed is SOAT1; the disease is cancer.